VALBIOTIS SA: Phase II/III REVERSE-IT Study to be Presented at 2023 EASD Congress

The Phase II/III clinical study REVERSE-IT, involving the active substance TOTUM•63, is set to be presented at the European Association for the Study of Diabetes (EASD) 2023 congress. This presentation will detail the study's protocol and the characteristics of the 636 volunteers involved, marking a significant step in the research of non-drug approaches to prediabetes and early stages of type 2 diabetes.

TOTUM•63, a patented combination of five plant extracts, targets the pathophysiological mechanisms of type 2 diabetes and has shown impressive efficacy in clinical trials. The REVERSE-IT study represents a breakthrough in the field, offering new perspectives for preventive healthcare solutions.

The oral communication at the EASD congress follows a presentation at the American Diabetes Association congress, highlighting the international recognition of the study's value. Valbiotis, a company focused on scientific innovation for preventing and combating metabolic and cardiovascular diseases, has developed TOTUM•63 as part of its commitment to addressing unmet medical needs through natural, clinically proven solutions.

This study's selection for presentation at two of the world's leading diabetes congresses underscores the scientific community's interest in innovative approaches to diabetes prevention and management. Valbiotis's partnership with Nestlé Health Science further emphasizes the potential global impact of TOTUM•63 in the health nutrition sector.